Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Diese Aktie meldet Mega-Deal: Nokia & Ericsson an Bord!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 895929 | ISIN: CH0012142631 | Ticker-Symbol: CLRN
Tradegate
15.09.25 | 15:08
8,710 Euro
+0,46 % +0,040
1-Jahres-Chart
CLARIANT AG Chart 1 Jahr
5-Tage-Chart
CLARIANT AG 5-Tage-Chart
RealtimeGeldBriefZeit
8,7358,75515.09.
8,7458,75015.09.
PR Newswire
577 Leser
Artikel bewerten:
(2)

LBB Specialties LLC: LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications

NORWALK, Conn., Dec. 4, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will distribute Clariant's pharmaceutical-grade high-functional excipients - including their polyethylene glycols (PEGs) and VitiPure® portfolio - for ophthalmic applications in the North American Life Sciences market.

LBB Specialties Logo

This partnership brings together LBB Specialties' established expertise in the ophthalmic market with Clariant's decades-long experience in producing and supplying high-quality PEGs, a critical component in many ophthalmic formulations.

Clariant's pharmaceutical-grade PEGs, now part of LBB Specialties' innovative Life Sciences portfolio, ensure customers have access to high-performance ingredients designed for various ophthalmic products. From eye drops to gels, the addition of these PEGs strengthens LBB Specialties' ability to meet the evolving demands of the pharmaceutical industry.

"At LBB Specialties, we're committed to providing our customers with the highest quality specialty pharmaceutical ingredients," said Seth Burns, Senior Vice President of Life Sciences at LBB Specialties. "Partnering with Clariant allows us to deliver industry-leading PEGs that offer consistency and performance for ophthalmic applications, providing our customers with the assurance they need throughout the pharmaceutical lifecycle-from R&D to commercialization."

"This partnership with LBB Specialties marks a significant step in our commitment to serving the pharmaceutical industry," said Vaios Barlas, Head of Health Care at Clariant. "Our focus on developing high-performance, pharmaceutical-grade excipients has consistently pushed the boundaries of what's possible in ophthalmic formulations. By leveraging LBB Specialties' strong distribution network in North America, we can ensure that more formulators and manufacturers can access our cutting-edge ingredients, ultimately driving innovation in ophthalmic applications."

To learn more about Clariant's PEGs and how they can benefit your products, contact LBB Specialties today.

About LBB Specialties
LBB Specialties is a leader in North American specialty chemicals and ingredients distribution. It is a diversified supplier serving end markets including care, food & nutrition, industrial specialties, and life sciences. www.LBBSpecialties.com.

About Clariant
Clariant is a focused specialty chemical company led by the overarching purpose of "Greater chemistry - between people and planet." By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On December 31, 2023, Clariant totaled a staff number of 10,481 and recorded sales of CHF 4.377 billion in the fiscal year for its continuing businesses. Since January 2023, the Group conducts its business through the three Business Units: Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland.

Clariant Health Care is a leading high-quality solution partner for the global pharmaceutical industry, with a strong portfolio of top-performing excipients and active pharmaceutical ingredients (APIs), backed by operational excellence and years of experience in regulatory affairs. https://www.clariant.com/HealthCare

Media Contact:
Ahmed Hanafy
media@lbbspecialties.com

Logo - https://mma.prnewswire.com/media/2537440/LBB_Specialties_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/lbb-specialties-and-clariant-partner-to-distribute-high-quality-pharmaceutical-grade-pegs-for-ophthalmic-applications-302322973.html

© 2024 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.